Investors will shortly be casting a keen eye on the progress of cancer biopharma companies given that the 2019 American Society of Clinical Oncology (ASCO) annual meeting, scheduled to take place in Chicago, is only about a month away. Prior to the release of the meeting abstracts, the presenting public companies will also be reporting their first-quarter earnings and business updates. That means there's no shortage of potential stock valuation-moving events in the near term. Read More
Therapeutic options have remained limited for the treatment of bipolar disorder (BD) where, according to the National Alliance on Mental Illness, about 2.6% of the U.S. population is diagnosed with the condition and nearly 83% of those cases classified as severe. Historically, there has been a lack of biopharma industry investment in neurology/psychiatric conditions. Read More
